Increased reporting of fatal pneumonitis associated with immune checkpoint inhibitors: a WHO pharmacovigilance database analysis Source: Eur Respir J, 55 (6) 2000038; 10.1183/13993003.00038-2020 Year: 2020
Management of pulmonary toxicity associated with immune checkpoint inhibitors Source: Eur Respir Rev, 28 (154) 190012; 10.1183/16000617.0012-2019 Year: 2019
A functional imaging study to investigate the relationship between pulmonary inflammation and systemic inflammation in COPD patients Source: International Congress 2016 – From microimaging to functional evaluation of the lung Year: 2016
Immune checkpoint inhibitor-associated interstitial lung diseases: some progress but still many issues Source: Eur Respir J, 50 (2) 1701319; 10.1183/13993003.01319-2017 Year: 2017
Relationships between lung physiology and airway and systemic inflammation: a cohort study in COPD Source: Eur Respir J 2006; 28: Suppl. 50, 144s Year: 2006
Interstitial lung disease induced by exogenous agents: factors governing susceptibility Source: Eur Respir J 2001; 18: 30S-42S Year: 2001
Comparative survival analysis between idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis: Retrospective cohort study. Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: mechanistic insights and prognostic markers Year: 2018
Assessment of innate immunity mediators in the lung of COPD patients: relation with disease manifestations Source: Virtual Congress 2020 – Host-microbe interactions and their influence on lung disease onset and severity Year: 2020
Histopathologic changes, cellular apoptosis, and pulmonary vasculitis, with related immunogenetic changes in schistosomal corpulmonale patients Source: Eur Respir J 2006; 28: Suppl. 50, 658s Year: 2006
The PD-1 immune checkpoint promotes lung damage in murine models of COPD-like inflammation Source: International Congress 2019 – Injury and repair: less is more Year: 2019
Low apoptosis rate as a reason of local immune cell accumulation in interstitial lung diseases (ILD). The role of cytokine network Source: Eur Respir J 2006; 28: Suppl. 50, 826s Year: 2006
The clinical benefits of immune checkpoint inhibitors for thymic carcinomas Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018
Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction Source: Eur Respir J 2008; 31: 1334-1356 Year: 2008
Modulation of oxidative stress pathway by arginase inhibition: Evaluation in an animal model of chronic pulmonary inflammation Source: Annual Congress 2010 - Regulation of airway pharmacology Year: 2010
Evolution of asthma in relation to the bronchial inflammatory phenotype: a follow-up study Source: International Congress 2018 – Asthma analysis Year: 2018
Presentation by an expert: Interactions between innate immunity, inflammation and structural cells in pulmonary disease Source: Lung Science Conference 2013 - Early origins and mechanisms of chronic lung disease Year: 2013
LSC 2011 Abstract: Suppression of antitumor immunity as a potential link between inflammation and cancer in COPD Source: Annual Congress 2011 - COPD: human studies Year: 2011
Relationship between markers of systemic inflammation and microstructural brain damage in COPD. Source: International Congress 2019 – From the health effects of tobacco to the epidemiology of tobacco/electronic nicotine delivery system use Year: 2019
Relationship of systemic inflammation and autoimmunity to clinically relevant outcomes in COPD Source: Annual Congress 2011 - COPD mechanisms Year: 2011
DNA damage as a molecular link in the pathogenesis of COPD in smokers Source: Eur Respir J 2012; 39: 1368-1376 Year: 2012